These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32301504)

  • 1. Oncolytic adenovirus ORCA-010 increases the type 1 T cell stimulatory capacity of melanoma-conditioned dendritic cells.
    López González M; van de Ven R; de Haan H; van Eck van der Sluijs J; Dong W; van Beusechem VW; de Gruijl TD
    Clin Exp Immunol; 2020 Aug; 201(2):145-160. PubMed ID: 32301504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma.
    Milenova I; Lopez Gonzalez M; Quixabeira DCA; Santos JM; Cervera-Carrascon V; Dong W; Hemminki A; van Beusechem VW; van de Ven R; de Gruijl TD
    Hum Gene Ther; 2021 Feb; 32(3-4):178-191. PubMed ID: 33470166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic adenovirus decreases the proportion of TIM-3
    Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature.
    Schierer S; Hesse A; Knippertz I; Kaempgen E; Baur AS; Schuler G; Steinkasserer A; Nettelbeck DM
    Int J Cancer; 2012 Apr; 130(7):1682-94. PubMed ID: 21557217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
    Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined p14ARF and Interferon-β Gene Transfer to the Human Melanoma Cell Line SK-MEL-147 Promotes Oncolysis and Immune Activation.
    Cerqueira OLD; Clavijo-Salomon MA; Cardoso EC; Citrangulo Tortelli Junior T; Mendonça SA; Barbuto JAM; Strauss BE
    Front Immunol; 2020; 11():576658. PubMed ID: 33193370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
    Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
    Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexamethasone turns tumor antigen-presenting cells into tolerogenic dendritic cells with T cell inhibitory functions.
    Falcón-Beas C; Tittarelli A; Mora-Bau G; Tempio F; Pérez C; Hevia D; Behrens C; Flores I; Falcón-Beas F; Garrido P; Ascui G; Pereda C; González FE; Salazar-Onfray F; López MN
    Immunobiology; 2019 Sep; 224(5):697-705. PubMed ID: 31221438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor immune response mediated by paclitaxel-conjugated nanohybrid oncolytic adenovirus with dendritic cell therapy.
    Kim IW; Yoon AR; Hong J; Kasala D; Yun CO
    Front Immunol; 2024; 15():1355566. PubMed ID: 38835775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
    Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
    J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
    Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
    Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
    Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA
    Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.
    Kim SY; Kang D; Choi HJ; Joo Y; Kim JH; Song JJ
    Oncotarget; 2017 Feb; 8(9):15858-15877. PubMed ID: 28178658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.
    Ahn HM; Hong J; Yun CO
    Oncotarget; 2016 Dec; 7(51):84965-84980. PubMed ID: 27821803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.
    Hangalapura BN; Oosterhoff D; Aggarwal S; Wijnands PG; van de Ven R; Santegoets SJ; van den Tol MP; Hooijberg E; Pereboev A; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD
    J Immunother; 2010 Sep; 33(7):706-15. PubMed ID: 20664356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
    Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
    BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.
    Huang JH; Zhang SN; Choi KJ; Choi IK; Kim JH; Lee MG; Lee M; Kim H; Yun CO
    Mol Ther; 2010 Feb; 18(2):264-74. PubMed ID: 19738604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.